This study tests the prevalence and characteristics of overlapping obesity, type 2 diabetes (T2D), cardiovascular disease (CVD), chronic kidney disease (CKD), and metabolic dysfunction-associated steatotic liver disease \[MASLD/Metabolic Dysfunction-Associated Steatohepatitis (MASH)\], osteoarthritis, hypertension, and dyslipidemia. The purpose of the study is to measure how common cardiovascular, kidney, and metabolic diseases are in the Korean adult population and how often they occur together (overlap) over time (2013-2023). Participants will not receive any study medicine as this is an observational analysis of existing survey data. The study does not involve a new investigational drug; it analyses health and outcome data collected in routine practice and national surveys.
Study Type
OBSERVATIONAL
Enrollment
800,000
No treatment given
Novo Nordisk Pharma Korea, Ltd.
Seoul, South Korea
Proportion of participants with obesity (BMI ≥25 kilograms per square meter (kg/m^2))
Measured in proportion (%).
Time frame: 2013-2018 (Annually)
Proportion of participants with T2D
Measured in proportion (%).
Time frame: 2013-2018 (Annually)
Proportion of participants with hypertension
Measured in proportion (%).
Time frame: 2013-2018 (Annually)
Proportion of participants with dyslipidemia
Measured in proportion (%).
Time frame: 2013-2018 (Annually)
Proportion of participants with CVD (ASCVD, HF with atrial fibrillation, HF without atrial fibrillation)
Measured in proportion (%).
Time frame: 2013-2018 (Annually)
Proportion of participants with CKD
Measured in proportion (%).
Time frame: 2013-2018 (Annually)
Proportion of participants with MASLD; at-risk Metabolic Dysfunction-Associated Steatohepatitis (MASH)(within MASLD)
Measured in proportion (%).
Time frame: 2013-2018 (Annually)
Proportion of participants with Osteoarthritis (OA)
Measured in proportion (%).
Time frame: 2013-2018 (Annually)
Multi-disease overlap (≥2, ≥3 conditions)
Measured in proportion (%).
Time frame: 2013-2018 (Annually)
Patient characteristics in obesity/diabetes-anchored strata
Measured as descriptive statistics.
Time frame: 2013-2018 (Annually)
Baseline characteristics by subgroup cohort
Measured as descriptive statistics.
Time frame: Cohort index date (2013-2018)
All-cause mortality over cohort follow-up
Measured in Hazard Ratio (HR).
Time frame: From cohort index date (entry restricted to 2013-2018; ≥5 yr potential follow up (FU))
Healthcare resource utilization (HCRU) over cohort follow-up (Number of participants)
Measured as outpatient visits, hospitalizations, and emergency room visits in terms of number of participants.
Time frame: From cohort index date (entry restricted to 2013-2018; ≥5 yr potential FU)
Healthcare resource utilization (HCRU) over cohort follow-up (rates per person-year)
Measured as outpatient visits, hospitalizations, and emergency room visits in terms of rates per person-year.
Time frame: From cohort index date (entry restricted to 2013-2018; ≥5 yr potential FU)
Total medical costs over cohort follow-up (Mean)
Measured as Cumulative total costs and annualized costs per person-year in terms of means with standard deviations.
Time frame: From cohort index date (entry restricted to 2013-2018; ≥5 yr potential FU)
Total medical costs over cohort follow-up (Median)
Measured as Cumulative total costs and annualized costs per person-year in terms of medians with Interquartile Range (IQR)
Time frame: From cohort index date (entry restricted to 2013-2018; ≥5 yr potential FU)
Three-point major adverse cardiovascular events (3P-MACE) composite assessment for CV-death proxy, non-fatal myocardial infarction, and non-fatal stroke
Measured in Hazard Ratio (HR).
Time frame: From cohort index date (entry restricted to 2013-2018; ≥5 yr potential (FU)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Proportion of participants with baseline organ-axis phenotype distribution (HF cohort): ASCVD, renal, metabolic, hepatic axes
Measured in proportion (%) by phenotype.
Time frame: Cohort index date (2013-2018)
Proportion of participants with GDMT prescription patterns, calendar-year trends, and prescription disparities (HF cohort)
Measured in proportion (%).
Time frame: Over cohort follow-up (2013-2023)
Time to CKM stage progression (CKM stage cohort)
Measured as median time to progression, if estimable; number and proportion with progression
Time frame: From cohort index date (entry restricted to 2013-2018; ≥5 years potential FU) to date of Progression
Time to tier change (High obesity cohort)
Measured as median time to tier change, if estimable; number and proportion with tier change.
Time frame: From cohort index date (entry restricted to 2013-2018; ≥5 years potential FU) to tier change